Intellia Therapeutics, Inc. (NTLA) is currently priced at $13.62, showing a price increase of 4.49% from the previous close. Trading volume is significantly higher at $5.85 million, up by 140.42% compared to the average.
In the latest quarterly earnings report on Wednesday, February 25th, Intellia Therapeutics reported a consensus estimate EPS of -0.99.
The company's free cash flow stands at -$69.41 million, while operating cash flow amounts to -$69.28 million. There was a net decrease in cash of $37.92 million.
Intellia Therapeutics generated revenue of $23 million with a gross profit of $17 million. Operating expenses totaled $115.71 million, resulting in a net income of -$95.79 million.
Key ratios include a quick ratio of 5.08, gross profit margin of 73.87%, and a debt ratio of 11.08. Notably, the company's price-to-book ratio is at 1.45.
Total assets amount to $842.13 million, with total liabilities at $170.73 million. Cash and cash equivalents stand at $155.46 million, while total investments reach $329.96 million.
This financial report provides insights into Intellia Therapeutics, Inc.'s current financial performance, highlighting key metrics and trends in the market.
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.